2,851
edits
Nicotinamide Mononucleotide (NMN): Difference between revisions
Nicotinamide Mononucleotide (NMN) (view source)
Revision as of 16:54, 31 October 2023
, 31 October 2023→Clinical Trials
No edit summary |
|||
| Line 178: | Line 178: | ||
* The improvement of aerobic capacity is in a dosage-dependent, large dosage of NMN with exercise has better effects. | * The improvement of aerobic capacity is in a dosage-dependent, large dosage of NMN with exercise has better effects. | ||
* The improvement is muscle, not cardiac, related. | * The improvement is muscle, not cardiac, related. | ||
|- | |||
| {{#pmid:36002548|#pmid_text}} | |||
|[[RCT]], 4 weeks | |||
* placebo (n=15) | |||
* 1250 mg/day (n=16) | |||
| | |||
* 31 healthy adult men and women | |||
* 20–65 years | |||
| | |||
* Oral administration of 1250 mg of NMN, when administered once daily for up to 4 weeks, was safe and well-tolerated in healthy adult men and women. | |||
* Oral administration of NMN in humans has a low adverse effect on renal function. | |||
* Results indicate that NMN can be administered orally to humans at doses 1250 mg once daily for up to 4 weeks without causing hepatotoxicity and vasodilative flushing, and is believed to have a higher upper tolerable limit compared to NAM and NA. | |||
|- | |- | ||
| {{#pmid:36482258|#pmid_text}} | | {{#pmid:36482258|#pmid_text}} | ||
| Line 195: | Line 208: | ||
* significant improvement of six-minute walking test, blood biological age, and SF-36 scores | * significant improvement of six-minute walking test, blood biological age, and SF-36 scores | ||
* 900 mg/day oral dose did not give significantly better efficacy than 600 mg/day dose | * 900 mg/day oral dose did not give significantly better efficacy than 600 mg/day dose | ||
|} | |} | ||